JP2016537380A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016537380A5 JP2016537380A5 JP2016532586A JP2016532586A JP2016537380A5 JP 2016537380 A5 JP2016537380 A5 JP 2016537380A5 JP 2016532586 A JP2016532586 A JP 2016532586A JP 2016532586 A JP2016532586 A JP 2016532586A JP 2016537380 A5 JP2016537380 A5 JP 2016537380A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- administered
- inh
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907550P | 2013-11-22 | 2013-11-22 | |
| US61/907,550 | 2013-11-22 | ||
| US201462029086P | 2014-07-25 | 2014-07-25 | |
| US62/029,086 | 2014-07-25 | ||
| PCT/US2014/066784 WO2015077543A1 (en) | 2013-11-22 | 2014-11-21 | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018194167A Division JP6620206B2 (ja) | 2013-11-22 | 2018-10-15 | 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016537380A JP2016537380A (ja) | 2016-12-01 |
| JP2016537380A5 true JP2016537380A5 (enExample) | 2017-12-07 |
| JP6431912B2 JP6431912B2 (ja) | 2018-11-28 |
Family
ID=52016153
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532586A Active JP6431912B2 (ja) | 2013-11-22 | 2014-11-21 | 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法 |
| JP2018194167A Active JP6620206B2 (ja) | 2013-11-22 | 2018-10-15 | 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法 |
| JP2018214342A Withdrawn JP2019023233A (ja) | 2013-11-22 | 2018-11-15 | 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法 |
| JP2021012833A Withdrawn JP2021063141A (ja) | 2013-11-22 | 2021-01-29 | 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法 |
| JP2022163044A Pending JP2022179637A (ja) | 2013-11-22 | 2022-10-11 | 臓器移植患者における抗体媒介性拒絶反応のｃ１－エステラーゼ阻害剤を使用した治療方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018194167A Active JP6620206B2 (ja) | 2013-11-22 | 2018-10-15 | 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法 |
| JP2018214342A Withdrawn JP2019023233A (ja) | 2013-11-22 | 2018-11-15 | 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法 |
| JP2021012833A Withdrawn JP2021063141A (ja) | 2013-11-22 | 2021-01-29 | 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法 |
| JP2022163044A Pending JP2022179637A (ja) | 2013-11-22 | 2022-10-11 | 臓器移植患者における抗体媒介性拒絶反応のｃ１－エステラーゼ阻害剤を使用した治療方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9895428B2 (enExample) |
| EP (3) | EP4162947A1 (enExample) |
| JP (5) | JP6431912B2 (enExample) |
| KR (2) | KR102312817B1 (enExample) |
| CN (2) | CN111388655A (enExample) |
| AU (2) | AU2014352846B2 (enExample) |
| BR (1) | BR112016011499A2 (enExample) |
| CA (1) | CA2930964A1 (enExample) |
| CY (1) | CY1121298T1 (enExample) |
| DK (1) | DK3071219T3 (enExample) |
| ES (1) | ES2708655T3 (enExample) |
| HR (1) | HRP20190184T1 (enExample) |
| HU (1) | HUE041809T2 (enExample) |
| LT (1) | LT3071219T (enExample) |
| ME (1) | ME03318B (enExample) |
| MX (2) | MX378834B (enExample) |
| NZ (2) | NZ719724A (enExample) |
| PL (1) | PL3071219T3 (enExample) |
| PT (1) | PT3071219T (enExample) |
| RS (1) | RS58343B1 (enExample) |
| SG (1) | SG10201804326SA (enExample) |
| SI (1) | SI3071219T1 (enExample) |
| SM (1) | SMT201900042T1 (enExample) |
| WO (1) | WO2015077543A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3071219T3 (pl) * | 2013-11-22 | 2019-04-30 | Shire Viropharma Inc | Sposoby leczenia zależnego od przeciwciała odrzucenia przeszczepu narządu u pacjentów za pomocą inhibitora esterazy c1 |
| CA3075686A1 (en) * | 2017-09-15 | 2019-03-21 | Cedars-Sinai Medical Center | Methods for improving organ function in organ transplant patients |
| WO2019166572A1 (en) * | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
| EP3897718A4 (en) * | 2018-12-20 | 2022-09-14 | Cedars-Sinai Medical Center | CLAZAKIZUMAB FOR THE TREATMENT OF CHRONIC ANTIBODY-MEDIATED REJECTION OF ORGAN TRANSPLANT |
| WO2021026507A1 (en) * | 2019-08-08 | 2021-02-11 | Cedars-Sinai Medical Center | Methods of improving organ function |
| EP3895726A1 (en) | 2020-04-17 | 2021-10-20 | Pharming Intellectual Property BV | Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress |
| CN116568327A (zh) * | 2020-11-20 | 2023-08-08 | 德国杰特贝林生物制品有限公司 | 治疗抗体介导的排斥反应的方法 |
| CN113035369B (zh) * | 2021-03-10 | 2021-12-03 | 浙江大学 | 一种肾移植抗感染药物剂量预测模型的构建方法 |
| US20240342258A1 (en) | 2021-07-09 | 2024-10-17 | Pharming Intellectual Property B.V. | Using c1 esterase inhibitor to treat viral infection-related symptoms |
| WO2024152030A1 (en) * | 2023-01-13 | 2024-07-18 | The Uab Research Foundation | Crossmatching for porcine xenotransplantation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4212278B2 (ja) * | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| DE10112617A1 (de) | 2001-03-14 | 2002-10-02 | Aventis Behring Gmbh | Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren |
| ES2516690T5 (es) | 2005-06-07 | 2017-11-21 | The Regents Of The University Of Colorado, A Body Corporate | Inhibidores de la actividad de serina proteasa y su uso en métodos y composiciones para el tratamiento de rechazo de injertos y promoción de supervivencia de injertos |
| EP1988882B1 (en) * | 2006-03-02 | 2014-12-17 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| EP2758076B1 (en) | 2011-09-24 | 2018-12-12 | CSL Behring GmbH | Combination therapy using immunoglobulin and c1-inhibitor |
| US10286047B2 (en) * | 2013-03-08 | 2019-05-14 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
| DE202014011208U1 (de) | 2013-03-15 | 2018-08-23 | Shire Viropharma Incorporated | C1-INH Zusammensetzungen für die Vorbeugung und Behandlung von Störungen, die mit C1-Esterasehemmer-Defizienz assoziiert sind |
| PL3071219T3 (pl) | 2013-11-22 | 2019-04-30 | Shire Viropharma Inc | Sposoby leczenia zależnego od przeciwciała odrzucenia przeszczepu narządu u pacjentów za pomocą inhibitora esterazy c1 |
-
2014
- 2014-11-21 PL PL14809567T patent/PL3071219T3/pl unknown
- 2014-11-21 MX MX2016006656A patent/MX378834B/es unknown
- 2014-11-21 SI SI201431066T patent/SI3071219T1/sl unknown
- 2014-11-21 ES ES14809567T patent/ES2708655T3/es active Active
- 2014-11-21 CN CN202010018792.0A patent/CN111388655A/zh active Pending
- 2014-11-21 NZ NZ719724A patent/NZ719724A/en unknown
- 2014-11-21 NZ NZ759187A patent/NZ759187A/en unknown
- 2014-11-21 AU AU2014352846A patent/AU2014352846B2/en active Active
- 2014-11-21 WO PCT/US2014/066784 patent/WO2015077543A1/en not_active Ceased
- 2014-11-21 EP EP22188379.6A patent/EP4162947A1/en active Pending
- 2014-11-21 ME MEP-2019-31A patent/ME03318B/me unknown
- 2014-11-21 RS RS20190148A patent/RS58343B1/sr unknown
- 2014-11-21 JP JP2016532586A patent/JP6431912B2/ja active Active
- 2014-11-21 DK DK14809567.2T patent/DK3071219T3/en active
- 2014-11-21 CN CN201480063697.5A patent/CN105744949A/zh active Pending
- 2014-11-21 EP EP14809567.2A patent/EP3071219B1/en not_active Revoked
- 2014-11-21 HR HRP20190184TT patent/HRP20190184T1/hr unknown
- 2014-11-21 KR KR1020167013463A patent/KR102312817B1/ko active Active
- 2014-11-21 BR BR112016011499-0A patent/BR112016011499A2/pt not_active Application Discontinuation
- 2014-11-21 HU HUE14809567A patent/HUE041809T2/hu unknown
- 2014-11-21 CA CA2930964A patent/CA2930964A1/en not_active Abandoned
- 2014-11-21 EP EP18205998.0A patent/EP3494988B1/en active Active
- 2014-11-21 PT PT14809567T patent/PT3071219T/pt unknown
- 2014-11-21 LT LTEP14809567.2T patent/LT3071219T/lt unknown
- 2014-11-21 SG SG10201804326SA patent/SG10201804326SA/en unknown
- 2014-11-21 US US14/550,075 patent/US9895428B2/en active Active
- 2014-11-21 KR KR1020217032180A patent/KR102384814B1/ko active Active
- 2014-11-21 SM SM20190042T patent/SMT201900042T1/it unknown
-
2016
- 2016-05-20 MX MX2021000332A patent/MX2021000332A/es unknown
-
2017
- 2017-12-18 US US15/844,850 patent/US20180104319A1/en not_active Abandoned
-
2018
- 2018-10-15 JP JP2018194167A patent/JP6620206B2/ja active Active
- 2018-11-15 JP JP2018214342A patent/JP2019023233A/ja not_active Withdrawn
-
2019
- 2019-01-29 CY CY20191100119T patent/CY1121298T1/el unknown
-
2020
- 2020-01-02 AU AU2020200015A patent/AU2020200015B2/en active Active
- 2020-08-03 US US16/983,998 patent/US20200360495A1/en not_active Abandoned
-
2021
- 2021-01-29 JP JP2021012833A patent/JP2021063141A/ja not_active Withdrawn
-
2022
- 2022-10-11 JP JP2022163044A patent/JP2022179637A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016537380A5 (enExample) | ||
| JP7788114B2 (ja) | ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ | |
| Winston et al. | Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients | |
| Johnson et al. | Prolonged use of oritavancin for vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis | |
| Al Jarroudi et al. | Anti-programmed cell death protein 1 (PD-1) immunotherapy for metastatic hepatocellular carcinoma after liver transplantation: a report of three cases | |
| Mahmud et al. | Antibody immunosuppressive therapy in solid-organ transplant: Part I | |
| KR20110074898A (ko) | 염증을 치료하는 방법 | |
| JP2017506626A5 (enExample) | ||
| JP2021063141A (ja) | 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法 | |
| Zanwar et al. | Ixazomib: a novel drug for multiple myeloma | |
| Sengsayadeth et al. | Time to explore preventive and novel therapies for bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation | |
| Snell et al. | A randomized, double-blind, placebo-controlled, multicenter study of rabbit ATG in the prophylaxis of acute rejection in lung transplantation | |
| JP2014505056A5 (enExample) | ||
| Liao et al. | Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review | |
| CN109640959A (zh) | 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积 | |
| Sadaka et al. | Proteasome inhibition for antibody-mediated allograft rejection | |
| Niemeyer et al. | Long-term safety, tolerability and efficacy of daclizumab (Zenapax®) in a two-dose regimen in liver transplant recipients | |
| Parrondo et al. | Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives | |
| Oury et al. | Protective effect of ticagrelor against infective endocarditis induced by virulent Staphylococcus aureus in mice | |
| Hsu et al. | Therapeutic effects of Anti-PD1 immunotherapy on hepatocellular carcinoma under administration of tacrolimus | |
| Marino et al. | Efficacy and safety of basiliximab with a tacrolimus-based regimen in liver transplant recipients | |
| Terpos et al. | Multiple myeloma: clinical updates from the American Society of Hematology Annual Meeting 2016 | |
| Wamala et al. | Recombinant anti-monkey CD3 immunotoxin depletes peripheral lymph node T lymphocytes more effectively than rabbit anti-thymocyte globulin in naive baboons | |
| Chong et al. | From bench to bedside: reversing established antibody responses and desensitization | |
| Sharma et al. | Beyond first-line immune checkpoint inhibitor therapy in patients with hepatocellular carcinoma |